Human CTLA-8 and uses of CTLA-8-related proteins

• US 6,043,344 A
• Filed: 03/04/1998
• Issued: 03/28/2000
• Est. Priority Date: 07/19/1995
• Status: Expired due to Term

• Current Assignee: Genetics Institute LLC (Pfizer Inc.)
• Original Assignee: Genetics Institute LLC (Pfizer Inc.)
• Inventors: Giannotti, Joanne, Carlin, McKeough, Pittman, Debra, Kelleher, Kerry, Neben, Steven, Golden-Fleet, Margaret M., Mi, Sha, Jacobs, Kenneth, Goldman, Samuel
• Primary Examiner(s): Draper, Garnette D.
• Application Number:
  US09/034,810
• Time in Patent Office: 755 Days
• Field of Search: 530/351, 530/350, 424/85.1
• US Class Current: 530/351
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/523 Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
• CPC Class Codes: C07K 14/54 Interleukins [IL]
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.

Claims

1. An isolated human CTLA-8 protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid of SEQ ID NO;

2;

(b) the amino acid sequence of SEQ ID NO;

2 from amino acids 11 to 163;

(c) the amino acid sequence of SEQ ID NO;

2 from amino acids 29 to 163;

(d) the amino acid sequence of SEQ ID NO;

2 from amino acids 31 to 163;

(e) a fragment of SEQ ID NO;

2, the fragment comprising amino acids 11-163 of SEQ ID NO;

2;

(f) a fragment of SEQ ID NO;

2, and the fragment comprising amino acids 29-163 of SEQ ID NO;

2;

(g) a fragment of SEQ ID NO;

2, the fragment comprising amino acids 31-163 of SEQ ID NO;

2.

2. The protein of claim 1 comprising the amino acid sequence of SEQ ID NO:

2.

3. The protein of claim 1 comprising the sequence from amino acid 29 to 163 of SEQ ID NO:

2.

4. The protein of claim 1 comprising the sequence from amino acid 11 to 163 of SEQ ID NO:

2.

5. The protein of claim 1 comprising a fragment of SEQ ID NO:

2, the fragment comprising amino acids 11-163 of SEQ ID NO;

2.

6. The protein of claim 1 comprising a fragment of SEQ ID NO:

2, the fragment comprising amino acids 29-163 of SEQ ID NO;

2.

7. The protein of claim 1 comprising a fragment of SEQ ID NO:

2, the fragment comprising amino acids 31-163 of SEQ ID NO;

2.

13. A pharmaceutical composition comprising a human CTLA-8 protein of claim 1 and a pharmaceutically acceptable carrier.

8. A human CTLA-8 protein produced according to a process which comprises the steps of:

(a) growing a culture of a cell in a suitable culture medium, wherein the cell is transformed with a polynucleotide operably linked to an expression control sequence, wherein the polynucleotide is selected from the group consisting of;

(aa) a polynucleotide comprising the nucleotide sequence of SEQ ID NO;

1 from nucleotide 55 to nucleotide 544;

(ab) a polynucleotide comprising the nucleotide sequence of SEQ ID NO;

1 from nucleotide 146 to nucleotide 544;

(ac) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone B18 deposited under accession number ATCC 69868;

(ad) a polynucleotide encoding the fill length protein encoded by the cDNA insert of clone B18 deposited under accession number ATCC 69868; and

(ae) a polynucleotide comprising a nucleotide sequence varying from the sequence of the nucleotide sequence specified in (aa)-(ad) as a result of degeneracy of the genetic code; and

(b) purifying the human CTLA-8 protein encoded by said polynucleotide from the culture.

9. The human CTLA-8 protein of claim 8, wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:

1 from nucleotide 55 to nucleotide 544.

10. The human CTLA-8 protein of claim 8 wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:

1 from nucleotide 146 to nucleotide 544.

11. The human CTLA-8 protein of claim 8, wherein said polynucleotide comprises the nucleotide sequence of the full-length protein coding sequence of clone B18 deposited under accession number ATCC 69868.

12. The human CTLA-8 protein of claim 8, wherein said polynucleotide comprises a polynucleotide encoding the full length protein encoded by the cDNA insert of clone B18 deposited under accession number ATCC 69868.